New combo therapy aims to lower radiation for lymphoma patients

NCT ID NCT03341520

First seen Apr 25, 2026 · Last updated May 14, 2026 · Updated 3 times

Summary

This study tested a new approach for people with early-stage follicular lymphoma, a slow-growing blood cancer. Instead of standard full-dose radiation, participants received a low dose of radiation combined with the drug Obinutuzumab (Gazyvaro). The goal was to see if this combination could achieve complete remission while reducing radiation side effects. The study involved 89 adults with untreated stage I or II disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for STAGE II GRADE 1 FOLLICULAR LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Klinikum Kempten

    Kempten, Germany

  • LMU

    Munich, 81377, Germany

  • Site Marburg

    Marburg, Germany

  • TU

    Munich, 81675, Germany

  • University of Cologne

    Cologne, 50924, Germany

  • University of Essen

    Essen, 45122, Germany

  • University of Frankfurt

    Frankfurt, 60590, Germany

  • University of Heidelberg

    Heidelberg, 69120, Germany

  • University of Muenster

    Münster, Germany

  • University of Tuebingen

    Tübingen, Baden-Wurttemberg, Germany

  • University of Ulm

    Ulm, 89081, Germany

  • Vivantes Klinikum

    Berlin, Germany

Conditions

Explore the condition pages connected to this study.